Hinova Pharmaceuticals Inc. (SHA:688302)
China · Delayed Price · Currency is CNY 48.08
-1.01 (-2.06%)
At close: Jan 22, 2026
Hinova Pharmaceuticals Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2018 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2018 - 2019 |
Operating Revenue | 23.24 | - | - | - | - | - | Upgrade |
Other Revenue | 0.37 | 0.37 | - | 1.65 | - | - | Upgrade |
| 23.61 | 0.37 | - | 1.65 | - | - | Upgrade | |
Revenue Growth (YoY) | 21414.67% | - | - | - | - | - | Upgrade |
Cost of Revenue | 0.34 | 0.34 | - | 0.77 | - | - | Upgrade |
Gross Profit | 23.27 | 0.03 | - | 0.88 | - | - | Upgrade |
Selling, General & Admin | 72.09 | 53.49 | 88 | 97.04 | 80.28 | 61.9 | Upgrade |
Research & Development | 129.49 | 174.03 | 248.27 | 251.37 | 264.93 | 428.93 | Upgrade |
Other Operating Expenses | -9.4 | 0.41 | 0.42 | 0.35 | 0.06 | 0.47 | Upgrade |
Operating Expenses | 192.76 | 227.94 | 336.69 | 348.75 | 345.27 | 491.3 | Upgrade |
Operating Income | -169.49 | -227.91 | -336.69 | -347.87 | -345.27 | -491.3 | Upgrade |
Interest Expense | -0.42 | -0.53 | -1.49 | -3.92 | -2.56 | -0.36 | Upgrade |
Interest & Investment Income | 14.18 | 19.16 | 28.62 | 22.5 | 26.97 | 7.41 | Upgrade |
Currency Exchange Gain (Loss) | 1.35 | 1.35 | 1.4 | 7.56 | -2.1 | -5.23 | Upgrade |
Other Non Operating Income (Expenses) | -0.31 | -0.43 | -0.38 | -0.17 | -0.14 | -10.06 | Upgrade |
EBT Excluding Unusual Items | -154.69 | -208.35 | -308.53 | -321.9 | -323.11 | -499.54 | Upgrade |
Gain (Loss) on Sale of Investments | 5.81 | 3.96 | 8.35 | 10.27 | -1.5 | - | Upgrade |
Gain (Loss) on Sale of Assets | -0 | -0 | -0.01 | -0 | -0 | - | Upgrade |
Asset Writedown | - | - | - | - | - | -0.02 | Upgrade |
Other Unusual Items | 4.31 | 4.91 | 6.04 | 10.12 | 18.44 | 9.71 | Upgrade |
Pretax Income | -144.57 | -199.48 | -294.14 | -301.51 | -306.18 | -489.85 | Upgrade |
Income Tax Expense | 0.01 | 0.01 | 0.02 | - | - | - | Upgrade |
Earnings From Continuing Operations | -144.57 | -199.5 | -294.16 | -301.51 | -306.18 | -489.85 | Upgrade |
Minority Interest in Earnings | - | - | - | - | - | 0 | Upgrade |
Net Income | -144.57 | -199.5 | -294.16 | -301.51 | -306.18 | -489.85 | Upgrade |
Net Income to Common | -144.57 | -199.5 | -294.16 | -301.51 | -306.18 | -489.85 | Upgrade |
Shares Outstanding (Basic) | 100 | 99 | 99 | 91 | 74 | 70 | Upgrade |
Shares Outstanding (Diluted) | 100 | 99 | 99 | 91 | 74 | 70 | Upgrade |
Shares Change (YoY) | 0.82% | 0.21% | 9.06% | 22.21% | 5.74% | - | Upgrade |
EPS (Basic) | -1.45 | -2.01 | -2.97 | -3.32 | -4.12 | -6.97 | Upgrade |
EPS (Diluted) | -1.45 | -2.01 | -2.97 | -3.32 | -4.12 | -6.97 | Upgrade |
Free Cash Flow | -163.74 | -276.63 | -354.68 | -384.13 | -247.6 | -246.16 | Upgrade |
Free Cash Flow Per Share | -1.65 | -2.79 | -3.58 | -4.23 | -3.33 | -3.50 | Upgrade |
Gross Margin | 98.56% | 8.43% | - | 53.57% | - | - | Upgrade |
Operating Margin | -717.89% | -62127.45% | - | -21072.49% | - | - | Upgrade |
Profit Margin | -612.36% | -54382.81% | - | -18264.53% | - | - | Upgrade |
Free Cash Flow Margin | -693.57% | -75410.46% | - | -23269.07% | - | - | Upgrade |
EBITDA | -167.57 | -225.83 | -334.4 | -345.96 | -342.22 | -490.1 | Upgrade |
D&A For EBITDA | 1.91 | 2.07 | 2.28 | 1.91 | 3.05 | 1.2 | Upgrade |
EBIT | -169.49 | -227.91 | -336.69 | -347.87 | -345.27 | -491.3 | Upgrade |
Revenue as Reported | 23.61 | 0.37 | - | 1.65 | - | - | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.